Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.GlobeNewsWire • 01/04/24
BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology TargetsPRNewsWire • 01/03/24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncologyGlobeNewsWire • 01/03/24
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301GlobeNewsWire • 12/19/23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101GlobeNewsWire • 12/09/23
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023GlobeNewsWire • 12/07/23
Landmark Bio Signs Multi-Year Agreement to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-CarePRNewsWire • 11/06/23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023GlobeNewsWire • 11/02/23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to AlfasigmaGlobeNewsWire • 10/30/23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosusGlobeNewsWire • 08/28/23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating OfficerGlobeNewsWire • 06/15/23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its BoardGlobeNewsWire • 06/12/23
Galapagos to showcase CAR-T point-of-care manufacturing and initial Phase 1/2 CLL data with CD19 CAR-T candidate, GLPG5201, at the EHA 2023 congressGlobeNewsWire • 06/05/23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositisGlobeNewsWire • 05/23/23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023GlobeNewsWire • 05/22/23